Quinolinyl RORγt Modulators for Th17 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-mediated inflammatory diseases, such as psoriasis and rheumatoid arthritis, have limitations in selectively targeting the Th17 pathway, particularly in modulating RORγt activity to effectively prevent or treat these conditions.
Innovation Solution
Development of substituted quinoline compounds that act as modulators of the nuclear receptor RORγt, specifically designed to inhibit the Th17 pathway by administering compounds of Formula I, which are capable of preventing, treating, or ameliorating RORγt-mediated inflammatory syndromes, disorders, or diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies targeting IL-12 or IL-23 are used to treat inflammatory diseases, then the Th17 pathway can be inhibited, but the treatment lacks selectivity and may affect other immune pathways
Solution Approach 1:
The patent applies local quality by designing RORγt modulators that specifically target the nuclear receptor RORγt expressed in Th17 cells, rather than broadly inhibiting IL-12 or IL-23 cytokines. This localized targeting approach achieves effective Th17 pathway inhibition while preserving other immune pathways, directly resolving the selectivity issue of prior antibody-based treatments
2Object-affected harmful factors
If broad immunosuppressive therapy is used to treat inflammatory diseases, then inflammation can be reduced, but the treatment lacks specificity and may cause unwanted side effects
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (RORγt nuclear receptor) that drives Th17 cell differentiation and inflammatory responses. By isolating and modulating this specific target rather than using broad immunosuppressants, the invention achieves effective inflammation reduction while minimizing unwanted side effects through precise pathway-specific intervention
3Ease of operation
If existing treatments are used for RORγt-mediated inflammatory diseases, then some symptom relief may be achieved, but the treatments are not sufficiently targeted to the Th17 pathway mechanism
Solution Approach 1:
The patent employs parameter changes by developing small molecule RORγt modulators with specific chemical structures (Formula I compounds) that can be precisely tuned to optimize binding affinity and selectivity for RORγt. This molecular-level precision in drug design enables highly targeted Th17 pathway modulation, significantly improving targeting precision over existing non-specific immunosuppressive therapies
Data Source
AI summary
The present invention comprises compounds of Formula (I): wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORyt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.